Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 292.37M | 291.65M | 279.06M | 266.83M | 256.71M | 244.83M |
Gross Profit | 193.56M | 193.71M | 184.04M | 175.68M | 165.68M | 155.49M |
EBITDA | 62.43M | 62.53M | 59.59M | 53.53M | 44.87M | 46.01M |
Net Income | 19.11M | 20.01M | 15.21M | 12.09M | 5.84M | 14.09M |
Balance Sheet | ||||||
Total Assets | 524.04M | 510.77M | 499.94M | 497.74M | 486.75M | 500.31M |
Cash, Cash Equivalents and Short-Term Investments | 113.32M | 97.22M | 71.13M | 53.91M | 51.95M | 46.49M |
Total Debt | 16.64M | 17.37M | 20.25M | 23.32M | 26.18M | 28.48M |
Total Liabilities | 161.23M | 151.41M | 159.19M | 163.68M | 147.73M | 166.25M |
Stockholders Equity | 362.81M | 359.36M | 340.75M | 334.06M | 339.02M | 334.06M |
Cash Flow | ||||||
Free Cash Flow | 42.36M | 29.52M | 35.96M | 26.09M | 17.04M | 17.07M |
Operating Cash Flow | 63.80M | 57.66M | 63.97M | 51.19M | 42.38M | 35.87M |
Investing Cash Flow | -34.10M | -33.97M | -56.60M | -28.39M | -25.72M | -110.41M |
Financing Cash Flow | -4.82M | -4.52M | -13.04M | -23.70M | -6.21M | -20.49M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $1.70B | ― | -15.97% | ― | 16.29% | 66.01% | |
64 Neutral | $846.47M | 44.38 | 5.40% | 0.45% | 3.36% | 7.51% | |
61 Neutral | $281.89M | ― | -19.80% | ― | 4.88% | 37.87% | |
60 Neutral | $1.37B | ― | -10.99% | ― | 10.24% | 2.63% | |
58 Neutral | $575.59M | ― | -48.23% | ― | 14.99% | -35.83% | |
54 Neutral | $1.48B | ― | -54.49% | ― | -2.54% | -322.03% | |
49 Neutral | AU$2.48B | 4.18 | -64.25% | 2.84% | 36.51% | 13.13% |
On May 29, 2025, HealthStream, Inc. held its annual meeting of shareholders where three directors were elected to the board for a three-year term. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent accounting firm for 2025 and approved a non-binding advisory resolution on executive compensation.
The most recent analyst rating on (HSTM) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on HealthStream stock, see the HSTM Stock Forecast page.
On May 8, 2025, HealthStream announced that its Board of Directors has approved a new share repurchase program, allowing the company to buy back up to $25 million of its outstanding common stock. This initiative, which will run until May 31, 2026, or until the maximum amount is spent, is subject to market conditions and regulatory requirements, and can be suspended or discontinued at any time.
On May 5, 2025, HealthStream announced its financial results for the first quarter of 2025, revealing a slight increase in revenue to $73.5 million, but a decline in operating income and net income compared to the same period in 2024. The company attributed these results to investments in platform and SaaS applications, as well as changes in revenue mix. The Board declared a quarterly cash dividend of $0.031 per share. Additionally, HealthStream updated its financial guidance for 2025, reflecting macroeconomic challenges and technology scaling issues, while maintaining a strong sales pipeline.